Research programme: anti-EGFR therapeutics - AlgenAlternative Names: BL-7030
Latest Information Update: 07 May 2012
At a glance
- Originator Algen Biopharmaceuticals
- Developer BioLineRx
- Mechanism of Action Epidermal growth factor inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Mar 2012 Discontinued - Preclinical for Cancer in Israel (unspecified route)
- 01 Jul 2011 Preclinical trials in Cancer in Israel (unspecified route)
- 01 Jul 2011 BL 7030 licensed to BioLineRx worldwide